These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 27828998)
1. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective. Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998 [TBL] [Abstract][Full Text] [Related]
2. Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks. Xu J; Wang P; Yang H; Zhou J; Li Y; Li X; Xue W; Yu C; Tian Y; Zhu F Biomed Res Int; 2016; 2016():2509385. PubMed ID: 27547755 [TBL] [Abstract][Full Text] [Related]
3. A systematic analysis of FDA-approved anticancer drugs. Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210 [TBL] [Abstract][Full Text] [Related]
4. Targeting the cancer kinome through polypharmacology. Knight ZA; Lin H; Shokat KM Nat Rev Cancer; 2010 Feb; 10(2):130-7. PubMed ID: 20094047 [TBL] [Abstract][Full Text] [Related]
5. Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules. Dutta D; Das R; Mandal C; Mandal C J Chem Inf Model; 2018 Jan; 58(1):68-89. PubMed ID: 29243930 [TBL] [Abstract][Full Text] [Related]
6. Drug sales confirm clinical advantage of multi-target inhibition of drug escapes by anticancer kinase inhibitors. Chen S; Yang SY; Chen Z; Tan Y; Jiang YY; Chen YZ Drug Dev Res; 2019 Mar; 80(2):246-252. PubMed ID: 30422335 [TBL] [Abstract][Full Text] [Related]
7. Network analysis of FDA approved drugs and their targets. Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560 [TBL] [Abstract][Full Text] [Related]
8. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS. Verkhivker GM Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172 [TBL] [Abstract][Full Text] [Related]
9. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome. Miljković F; Bajorath J J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic polypharmacology: from combination therapy to multitargeted drugs. de Lera AR; Ganesan A Clin Epigenetics; 2016; 8():105. PubMed ID: 27752293 [TBL] [Abstract][Full Text] [Related]
11. A historical overview of protein kinases and their targeted small molecule inhibitors. Roskoski R Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888 [TBL] [Abstract][Full Text] [Related]
12. Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: a new approach for target discovery. van der Sligte NE; Scherpen FJ; Meeuwsen-de Boer TG; Lourens HJ; Ter Elst A; Diks SH; Guryev V; Peppelenbosch MP; van Leeuwen FN; de Bont ES Proteomics; 2015 Apr; 15(7):1245-54. PubMed ID: 25422122 [TBL] [Abstract][Full Text] [Related]
13. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles. Bailey FP; Andreev VI; Eyers PA Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644 [TBL] [Abstract][Full Text] [Related]
14. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126 [TBL] [Abstract][Full Text] [Related]
15. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362 [TBL] [Abstract][Full Text] [Related]
16. Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation. Li X; Li Z; Wu X; Xiong Z; Yang T; Fu Z; Liu X; Tan X; Zhong F; Wan X; Wang D; Ding X; Yang R; Hou H; Li C; Liu H; Chen K; Jiang H; Zheng M J Med Chem; 2020 Aug; 63(16):8723-8737. PubMed ID: 31364850 [TBL] [Abstract][Full Text] [Related]
17. Trends in kinase drug discovery: targets, indications and inhibitor design. Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255 [TBL] [Abstract][Full Text] [Related]
18. KinomeMETA: meta-learning enhanced kinome-wide polypharmacology profiling. Ren Q; Qu N; Sun J; Zhou J; Liu J; Ni L; Tong X; Zhang Z; Kong X; Wen Y; Wang Y; Wang D; Luo X; Zhang S; Zheng M; Li X Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38113075 [TBL] [Abstract][Full Text] [Related]
19. Polypharmacology of Approved Anticancer Drugs. Amelio I; Lisitsa A; Knight RA; Melino G; Antonov AV Curr Drug Targets; 2017; 18(5):534-543. PubMed ID: 26926468 [TBL] [Abstract][Full Text] [Related]
20. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database. Barneh F; Jafari M; Mirzaie M Brief Bioinform; 2016 Nov; 17(6):1070-1080. PubMed ID: 26490381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]